Human Studies on Pinealon
Interest in human trials on Pinealon has grown with increasing focus on bioregulatory peptides and interventions supporting healthy ageing. However, when evaluating available data, it is important to note that clinical evidence in humans remains limited. Although several human studies have been published, the evidence base is considerably smaller than for most conventional pharmaceutical therapies.
One of the main human studies was conducted by Meshchaninov and colleagues, involving 32 adults aged between 41 and 83 years who suffered from chronic multimorbidity and organic brain syndrome in remission (1). The researchers assessed the effects of Pinealon and another bioregulatory peptide, Vesugen, on biomarkers of biological ageing and indicators of the organism's functional state.
Scientists have noted that Pinealon induced significant anabolic effects and was associated with improved central nervous system (CNS) activity and the function of several important organs (1). According to the study's authors, these changes corresponded to a slowdown in biological ageing markers. The researchers concluded that Pinealon exhibits both neuroprotective and geroprotective properties that can support healthy ageing and the maintenance of functional fitness in older adults.
The study also included an assessment of numerous cellular and metabolic markers associated with ageing. Although Pinealon demonstrated a beneficial effect on functional outcomes, the researchers noted that its geroprotective effects appeared somewhat less pronounced than those observed with Vesugen in the same study (1). Nevertheless, the authors considered Pinealon a potential neuroprotective and geroprotective peptide worthy of further evaluation in elderly populations.
Despite these promising observations, several limitations should be taken into account. The study included a relatively small number of participants, lacked the scale usually required to draw firm clinical conclusions, and focused on a specific patient group (1). Further studies involving larger and more diverse populations are necessary to confirm these findings.
Currently, there are no large, multi-centre, randomised controlled trials evaluating Pinealon for cognitive decline, Alzheimer's disease, healthy ageing, or other clinical indications. Similarly, searches of publicly available clinical trial databases reveal a relatively small number of registered human trials compared to more extensively studied therapeutic compounds.
Generally speaking, current human study data suggest that Pinealon may affect central nervous system function and biomarkers associated with biological ageing. However, available clinical data remain preliminary, and further well-designed clinical trials are needed before definitive conclusions can be drawn regarding its efficacy, safety, and therapeutic potential in humans.
Safety and Side Effects of Pinealon
The data currently available indicates that Pinealon is generally well-tolerated in both experimental animal studies and a limited number of human studies conducted to date. However, as clinical data in humans remains relatively sparse, its overall safety profile has not yet been fully characterised, particularly with regard to long-term use.
The most valuable data regarding safety come from the study by Meshchaninov and colleagues, which involved 32 adults aged 41 to 83 years with chronic comorbidity and organic brain syndrome in remission (1). The researchers noted improvements in central nervous system function and biomarkers of biological ageing, with no significant safety issues detected during the study period. Importantly, Pinealon did not appear to negatively affect chromatin condensation, leading the authors to conclude that the peptide demonstrates safety at the level of nuclear genetic stability under the tested conditions (1).
Animal and cellular studies also indicate a favourable safety profile. Studies evaluating Pinealon's impact on oxidative stress, neuronal survival, and cognitive functions have typically shown protective rather than detrimental effects (2–4). In experimental models, Pinealon reduced oxidative damage, limited reactive oxygen species accumulation, improved neuronal viability, and decreased cell necrosis, without signs of significant toxicity at the tested doses (2,3).
Despite promising results, several important limitations should be considered. Human studies remain limited in participant numbers and duration, making it difficult to identify rare adverse events and fully assess long-term safety. Furthermore, large-scale randomised controlled trials specifically designed to evaluate safety have not yet been conducted.
Consequently, the long-term safety profile of Pinealon remains uncertain. Issues regarding chronic use, repeated treatment cycles, potential drug interactions, and use in specific populations have not been adequately investigated in large clinical trials. Individuals with pre-existing medical conditions should consult with a qualified healthcare professional before considering the use of any experimental peptide.
Based on the currently available data, Pinealon appears to be well tolerated in research settings, and no significant safety signals have been identified in published studies. However, the limited scope of human studies means that further clinical trials are needed before comprehensive safety conclusions can be drawn.
FDA Approval of Pinealon and Regulatory Status
Many people looking for information about Pinealon want to determine if it has been approved by the US Food and Drug Administration (FDA) and if it is considered an approved drug in the United States. Based on currently available regulatory information, Pinealon has not been approved by the FDA for the treatment, prevention, or diagnosis of any medical condition.
Searches of publicly available FDA drug databases do not indicate Pinealon as an approved prescription drug. Similarly, Pinealon does not appear in the Drugs@FDA database as an approved therapeutic product. This means Pinealon has not undergone the extensive regulatory review process required for pharmaceutical approval in the United States.
Instead, Pinealon is generally recognised as an experimental bioregulator peptide or a research peptide. Most of the scientific evidence currently available comes from laboratory studies, animal studies and a limited number of human trials mainly conducted in Russia and Eastern Europe (1–4). Although these studies have shown potentially beneficial biological effects, they are insufficient to warrant FDA approval or establish recognised medical indications.
A lack of FDA approval does not automatically mean that a compound does not exhibit biological activity. Instead, it signifies that sufficient evidence regarding its safety, efficacy, manufacturing quality, and clinical benefits has not been presented and approved within the FDA's regulatory process.
Researchers continue to analyse Pinealon for potential applications related to neuroprotection, cognitive function, oxidative stress regulation, and healthy ageing. However, these areas remain experimental, and currently, no major regulatory body recognises Pinealon as an approved therapy for neurological disorders, age-related conditions, or any other medical indication.
Therefore, Pinealon should currently be treated as a research compound, rather than an approved pharmaceutical product. Individuals interested in Pinealon should be aware that claims regarding its therapeutic effects are primarily based on preclinical data and a limited number of human studies, rather than established regulatory approval.
Disclaimer
The content is purely educational and informational in nature and should not be interpreted as medical advice, diagnosis, treatment, or professional recommendations. Pinealon has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or most other regulatory bodies for the treatment of cognitive decline, neurological disorders, age-related conditions, or any other medical indication. Most available data comes from preclinical studies and a limited number of human studies, many of which involved small study populations. Further well-designed clinical trials are needed to better determine the efficacy, safety, long-term effects, and potential therapeutic applications of Pinealon in various populations.
References
(1) Meshchaninov, V. N., Tkachenko, E. L., Zharkov, S. V., Gavrilov, I. V., & Katyreva, Y. E. (2015). The effect of synthetic peptides on the ageing of patients with chronic polymorbidity and organic cerebral syndrome in remission. Advances in Gerontology, 28(1), 62–67.
PubMed: https://pubmed.ncbi.nlm.nih.gov/26390612/
(2) Arutjunyan, A. V., Kozina, L. S., Stvolinsky, S. L., Bulygina, E. R., Mashkina, A. P., & Khavinson, V. K. (2012). Pinealon protects rat pups from prenatal hyperhomocysteinemia. International Journal of Peptides, 2012, 109757. https://doi.org/10.1155/2012/109757
PubMed: https://pubmed.ncbi.nlm.nih.gov/22567179/
PMC Full Text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3342713/
(3) Khavinson, V., Ribakova, Y., Trofimova, S., et al. (2011). Pinealon increases cell viability by suppressing free radical levels and activating proliferative processes.. Rejuvenation Research, 14(5), 517–523. https://doi.org/10.1089/rej.2011.1172
Journal Link: https://journals.sagepub.com/doi/abs/10.1089/rej.2011.1172
(4) Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotective effects of tripeptides—epigenetic regulators in a mouse model of Alzheimer’s disease. Pharmaceuticals, 14(6), 515. https://doi.org/10.3390/ph14060515
Journal Link: https://www.mdpi.com/1424-8247/14/6/515